search
Back to results

Antiretroviral Regime for Viral Eradication in Newborns

Primary Purpose

HIV/AIDS and Infections

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Zidovudine
Nevirapine
Lamivudine
Lopinavir/ritonavir
Sponsored by
National Center for Women and Children's Health, China CDC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV/AIDS and Infections focused on measuring HIV, antiretroviral treatment, child, testing

Eligibility Criteria

0 Days - 1 Day (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • children whose mother with HIV infection
  • children whose mother received antiretroviral drugs after 36 gestational weeks or received no drugs before delivery
  • live birth

Exclusion Criteria:

  • birth weight is less than 2000g
  • Apgar score is less than 3 at 1 minute after birth or less than 6 at 5 minute after birth .

Sites / Locations

  • Maternal and Child Health Hospital of Guangdong Province
  • Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
  • Maternal and Child Health Hospital of Sichuan Province
  • Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region
  • Maternal and Child Health Hospital of Yunan Province

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention group

Control group

Arm Description

Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.

Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.

Outcomes

Primary Outcome Measures

HIV infection in children
Number of children diagnosed with HIV infection
Functional HIV cure in children
Number of children with functional HIV cure

Secondary Outcome Measures

Mortality
Number of children died
ART regime for HIV exposed children at high risk of infection
ART regime to be used for functional HIV cure in children
Testing algorithm for early infant diagnosis of HIV
Testing methods and algorithm for HIV exposed infants

Full Information

First Posted
March 14, 2016
Last Updated
September 27, 2022
Sponsor
National Center for Women and Children's Health, China CDC
Collaborators
National Center for AIDS/STD Control and Prevention, China CDC, Maternal and Child Health Hospital of Yunan Province, Maternal and Child Health Hospital of Sichuan Province, Maternal and Child Health Hospital of Guangxi Province, Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Guangdong Provincial Maternal and Child Health Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02712801
Brief Title
Antiretroviral Regime for Viral Eradication in Newborns
Official Title
Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
December 2021 (Actual)
Study Completion Date
December 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Center for Women and Children's Health, China CDC
Collaborators
National Center for AIDS/STD Control and Prevention, China CDC, Maternal and Child Health Hospital of Yunan Province, Maternal and Child Health Hospital of Sichuan Province, Maternal and Child Health Hospital of Guangxi Province, Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Guangdong Provincial Maternal and Child Health Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multi-center, randomized, controlled, open clinical trial. The trial will be carried out in five provinces in China. Pregnant women with HIV infection and at high risk of mother-to-child transmission of HIV will be identified. Their newborn babies who are at high risk HIV infection will be recruited and randomized into intervention and control groups. Children in intervention groups will receive ART and intensive HIV testing after birth. Children in control group will receive routine prevention of mother-to-child transmission services. All the included children will be followed up and their development and infection status will be recorded and compared.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV/AIDS and Infections
Keywords
HIV, antiretroviral treatment, child, testing

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
600 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
Intervention Type
Drug
Intervention Name(s)
Zidovudine
Other Intervention Name(s)
AZT
Intervention Description
Dose will be adjusted according to the child's weight.
Intervention Type
Drug
Intervention Name(s)
Nevirapine
Other Intervention Name(s)
NVP
Intervention Description
Dose will be adjusted according to the child's weight.
Intervention Type
Drug
Intervention Name(s)
Lamivudine
Other Intervention Name(s)
3TC
Intervention Description
Dose will be adjusted according to the child's weight.
Intervention Type
Drug
Intervention Name(s)
Lopinavir/ritonavir
Other Intervention Name(s)
LPV/r
Intervention Description
Dose will be adjusted according to the child's weight.
Primary Outcome Measure Information:
Title
HIV infection in children
Description
Number of children diagnosed with HIV infection
Time Frame
0-18 months old
Title
Functional HIV cure in children
Description
Number of children with functional HIV cure
Time Frame
0-36 months old
Secondary Outcome Measure Information:
Title
Mortality
Description
Number of children died
Time Frame
0-36 months old
Title
ART regime for HIV exposed children at high risk of infection
Description
ART regime to be used for functional HIV cure in children
Time Frame
0-36 months old
Title
Testing algorithm for early infant diagnosis of HIV
Description
Testing methods and algorithm for HIV exposed infants
Time Frame
0-4 weeks old

10. Eligibility

Sex
All
Minimum Age & Unit of Time
0 Days
Maximum Age & Unit of Time
1 Day
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: children whose mother with HIV infection children whose mother received antiretroviral drugs after 36 gestational weeks or received no drugs before delivery live birth Exclusion Criteria: birth weight is less than 2000g Apgar score is less than 3 at 1 minute after birth or less than 6 at 5 minute after birth .
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xi Jin, M.D.
Organizational Affiliation
National Center for Women and Children's Health, China CDC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maternal and Child Health Hospital of Guangdong Province
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Name
Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
City
Nanning
State/Province
Guangxi
Country
China
Facility Name
Maternal and Child Health Hospital of Sichuan Province
City
Chengdu
State/Province
Sichuan
Country
China
Facility Name
Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region
City
Urumqi
State/Province
Xinjiang
Country
China
Facility Name
Maternal and Child Health Hospital of Yunan Province
City
Kunming
State/Province
Yunnan
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Antiretroviral Regime for Viral Eradication in Newborns

We'll reach out to this number within 24 hrs